Better answers with Prolaris

Clearly and confidently understand which cancer treatment option is right for you.

Get our testing guide

Better answers with Prolaris

Clearly and confidently understand which cancer treatment option is right for you.

Get our testing guide

Go Beyond Your Gleason Score

Gleason scoring plays a vital role in determining prostate cancer treatment decisions. Since the 1970s, Gleason has been used to assess the aggressiveness of a patient’s prostate cancer. Unfortunately, Gleason grading and scoring can be largely subjective, in fact, 34% of the time, expert-trained Pathologists disagree about biopsy Gleason scores1. This is where the Prolaris test comes in.

Get our testing guide

What is Prolaris? 

Prolaris is an advanced genetic test that combines tools like and with a personalized tumor score to determine how aggressive your prostate cancer is. Prolaris helps you decide which treatment option is best based on your cancer.

Is Prolaris right for me? 

Prolaris is for any untreated man with prostate cancer and helps you answer your most pressing questions like:

  • Am I safe for active surveillance or do I need treatment?
  • Is my cancer at risk of spreading?
  • What are my chances of surviving prostate cancer?
  • Can I benefit from adding hormone therapy (ADT) to radiation or can I safely avoid the side-effects of ADT?
Get our testing guide

65%

In two clinical utility studies, Prolaris results lead to change in management in up to 65% of patients.2,3,4

2x

The Prolaris score is 2x more prognostic than PSA and Gleason score combined5

$0

97% of patients pay $0 out of pocket

Prolaris Patient story

“Prolaris gave me the ability to maintain the lifestyle that my wife and I have lived with for many years now.”

Tim Petracca

Hear Tim’s story

The Prolaris Advantage

When it comes to making active surveillance or definitive treatment decisions, choosing the correct genetic test matters. Prolaris goes beyond risk-stratification with two-validated thresholds to determine which patients are safe for active surveillance, which patients need treatment, and how much treatment is needed.

Product Comparison Prolaris Decipher GPS Artera Ref
Can the test predict the risk of death from prostate cancer if the patient is choosing active surveillance? Y N N N Prolaris6,19
Was the active surveillance threshold validated on a group of untreated patients? Y N N N
Combines Gleason score and PSA with a personalized cancer aggressiveness score Y Y Y N
Can the test predict risk of cancer spreading outside the prostate after treatment? Y Y Y Y Artera7,8
Decipher9-12
GPS13
Prolaris6, 14-17
Does the test give a personalized risk number from adding hormone therapy (ADT) after radiation therapy? Y N N N Prolaris18

Myriad is here for you

Contact our trusted advisors for personalized support.

Learn how genetic testing can provide better answers for the best prostate cancer treatment for you in our FREE Patient Testing Guide.

References:

  1. Allsbrook WC, Mangold KA, Johnson MH, et al. Interobserver reproducibility of Gleason grading of prostatic carcinoma: Urologic pathologists. Hum. Pathol. 2001;32(1):74-80. doi:https://doi.org/10.1053/hupa.2001.21134
  2. Crawford ED, Scholz MC, Kar AJ, et al. Cell Cycle Progression Score and Treatment Decisions in Prostate Cancer:Results From an Ongoing Registry. Curr Med Res Opin 2014; 1-7
  3. Shore, N D., et al. Impact of the cell cycle progression test of physician and patient treatment selection for localized prostate cancer. The Journal of Urology 2016;195(3),612- 618
  4. Lin, D. W., et al. Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance. Urologic Oncology: Seminars and Original Investigations. 2018; doi: 10.1016/j.urolonc.2018.03.011.
  5. Cuzick J, et al. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. BJC 2012;106(6):1095-109
  6. Hutten RJ, Odei B, Johnson SB, Tward JD: Validation of the Combined Clinical Cell-Cycle Risk Score to Prognosticate Early Prostate Cancer Metastasis From Biopsy Specimens and Comparison With Other Routinely Used Risk Classifiers. JCO Precis Oncol 8:e2300364, 2024
  7. Esteva A, Feng J, van der Wal D, et al: Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials. npj Digital Medicine 5:71, 2022
  8. Spratt DE, Tang S, Sun Y, et al: Artificial Intelligence Predictive Model for Hormone Therapy Use in Prostate Cancer. 4. Res Sq, 2023
  9. Nguyen PL, Haddad Z, Ross AE, et al: Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens. Eur Urol 72:845-852, 2017
  10. Spratt DE, Zhang J, Santiago-Jiménez M, et al: Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer. J Clin Oncol 36:581-590, 2018
  11. Klein EA, Haddad Z, Yousefi K, et al: Decipher Genomic Classifier Measured on Prostate Biopsy Predicts Metastasis Risk. Urology 90:148-152, 2016
  12. Spratt DE, Huang H-C, Michalski JM, et al: Validation of the performance of the Decipher biopsy genomic classifier in intermediate-risk prostate cancer on the phase III randomized trial NRG Oncology/RTOG 0126, American Society of Clinical Oncology, 2022
  13. Berlin A, Murgic J, Hosni A, et al: Genomic Classifier for Guiding Treatment of Intermediate-Risk Prostate Cancers to Dose-Escalated Image Guided Radiation Therapy Without Hormone Therapy. International Journal of Radiation Oncology*Biology*Physics 103:84-91, 2019
  14. Cullen J, Kuo HC, Shan J, et al: The 17-Gene Genomic Prostate Score Test as a Predictor of Outcomes in Men with Unfavorable Intermediate Risk Prostate Cancer. Urology 143:103-111, 2020
  15. Canter DJ, Freedland S, Rajamani S, et al: Analysis of the prognostic utility of the cell cycle progression (CCP) score generated fromneedle biopsy in men treated with definitive therapy. Prostate Cancer and Prostatic Diseases 23:102-107, 2020
  16. Canter DJ, Reid J, Latsis M, et al: Comparison of the Prognostic Utility of the Cell Cycle Progression Score for Predicting Clinical Outcomes in AfricanAmerican and Non-African American Men with Localized Prostate Cancer. European Urology 75:515-522, 2019
  17. Tward J, Lenz L, Flake II DD, et al: The clinical cell-cycle risk (CCR) score is associated with metastasis after radiation therapy and provides guidance on when to forgo combined androgen deprivation therapy with dose-escalated radiation. International Journal of Radiation Oncology* Biology* Physics113:66-76, 2022
  18. Tward JD, Schlomm T, Bardot S, et al: Personalizing localized prostate cancer: validation of a combined clinical cell-cycle risk (CCR)score threshold for prognosticating benefit from multimodality therapy. Clinical genitourinary cancer 19:296-304. e3, 2021
  19. Brawer MK, Cooperberg MR, Freedland SJ, et al: Development and validation of a multivariate model combining cell cycle progression score with CAPRA to predict prostate cancer mortality in a conservatively managed cohort. Journal of Clinical Oncology31:67-67, 2013

Locations

United States
Europe
Japan